EP3268737A1 - Sample processing improvements for quantitative microscopy - Google Patents

Sample processing improvements for quantitative microscopy

Info

Publication number
EP3268737A1
EP3268737A1 EP16760984.1A EP16760984A EP3268737A1 EP 3268737 A1 EP3268737 A1 EP 3268737A1 EP 16760984 A EP16760984 A EP 16760984A EP 3268737 A1 EP3268737 A1 EP 3268737A1
Authority
EP
European Patent Office
Prior art keywords
thin film
sample
diluted sample
images
optical microscopy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16760984.1A
Other languages
German (de)
French (fr)
Other versions
EP3268737A4 (en
Inventor
Alan Marc Fine
Hershel MACAULAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alentic Microscience Inc
Original Assignee
Alentic Microscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alentic Microscience Inc filed Critical Alentic Microscience Inc
Publication of EP3268737A1 publication Critical patent/EP3268737A1/en
Publication of EP3268737A4 publication Critical patent/EP3268737A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00Sampling; Preparing specimens for investigation
    • G01N1/28Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/38Diluting, dispersing or mixing samples
    • G01N15/1433
    • GPHYSICS
    • G02OPTICS
    • G02BOPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B21/00Microscopes
    • G02B21/36Microscopes arranged for photographic purposes or projection purposes or digital imaging or video purposes including associated control and data processing arrangements
    • G01N2015/012
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N2015/1006Investigating individual particles for cytology
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10Investigating individual particles
    • G01N15/14Electro-optical investigation, e.g. flow cytometers
    • G01N2015/1486Counting the particles

Definitions

  • This specification generally describes technology related to sample processing for quantitative microscopy.
  • CBC hemoglobin
  • RBCs red blood cells
  • a method for computing mean corpuscular hemoglobin can include: generating a diluted sample based on mixing a small sample of blood with one or more diluents; forming a thin film of the diluted sample on a surface of a contact optical microscopy sensor; illuminating red blood cells within a portion of the thin film of the diluted sample using light of a predetermined wavelength; acquiring one or more images of the diluted sample based on illuminating the red blood cells within the portion of the thin film of the diluted sample; processing the acquired one or more images of the diluted sample; and determining a value of mean corpuscular hemoglobin in the red blood cells within the portion of the thin film of the diluted sample based on processing the acquired images of the diluted sample.
  • forming a thin film includes forming a thin film between a transparent chamber lid and the surface of the contact optical microscopy sensor.
  • forming a thin film between the lid and the contact optical microscopy sensor includes: placing the diluted sample on a surface of the contact optical microscopy sensor; and lowering the transparent chamber lid to a predetermined height determined by a spacer.
  • the size of the predetermined height is configured such that lowering of the transparent chamber lid onto the surface of the contact optical microscopy sensor (i) constrains the red blood cells to lie within a broadest dimension of the red blood cells parallel to the surface of the contact optical microscopy sensor, and (ii) does not result in structural damage to the red blood cells.
  • the one or more images of the diluted sample that are acquired include image features of at least one hundred red blood cells.
  • the predetermined wavelength comprises a wavelength that corresponds to a wavelength within the absorbance band of a form of hemoglobin with the highest extinction coefficient of that form of hemoglobin.
  • processing the acquired images of the diluted sample includes: estimating a background pixel value for each pixel within the respective acquired images;
  • the generated diluted sample has an isotonicity that is substantially equal to an isotonicity of red blood cells; has coagulation properties such that the generated diluted sample is less likely to coagulate compared to coagulation properties of red blood cells; and maintains a predetermined pH level of the generated diluted sample.
  • the acquired one or more images include at least a statistically significant number of the red blood cells in the diluted sample.
  • At least one of the one or more diluents comprises a nitrite.
  • generating a diluted sample comprises generating a diluted sample based on mixing the sample of blood with a diluent such that the mixing results in sphering of the red blood cells within the diluted sample.
  • a method for computing a mean amount of a measured analyte within a fluid sample can include: forming a thin film of a fluid sample on a surface of a contact optical microscopy sensor, the fluid sample comprising particulate matter that includes an analyte to be measured, the analyte having a distinctive absorption spectrum; illuminating at least a portion of the thin film of the fluid sample using white light of a predetermined wavelength; acquiring one or more images of the fluid sample based on illuminating at least a portion of the thin film of the fluid sample using white light of a predetermined; wavelength; processing the acquired one or more images of the fluid sample; and determining a value of a mean amount of the analyte based on processing the one or more images of the fluid sample.
  • forming a thin film includes forming a thin film between a transparent chamber lid and the contact optical microscopy sensor. [0018] In some implementations, forming a thin film between the lid and the surface of the contact optical microscopy sensor includes: placing the fluid sample on a surface of the contact optical microscopy sensor and lowering the transparent chamber lid to a predetermined height determined by a spacer.
  • the size of the predetermined height is configured such that lowering of the transparent chamber lid onto the surface of the contact optical microscopy sensor (i) constrains the particulate matter of the sample fluid to lie within a broadest dimension of the particular matter to the surface of the contact optical microscopy sensor, and (ii) does not result in structural damage to the particulate matter of the sample fluid.
  • processing the one or more acquired images includes:
  • forming a thin film includes: placing the fluid sample on the surface of the contact optical microscopy sensor; and enabling the thin film of the fluid sample formed on a surface of a contact optical microscopy sensor to settle.
  • FIG. 1 is graph of hemoglobin absorption spectra.
  • FIG. 2 is a contact optical microscopy image of a blood cell.
  • the bulk and complexity of the conventional CBC process can be overcome with the use of contact optical microscopy (COM)-based microspectrometry.
  • COM-based microspectrometry molecules in individual pixels and regions in a microscopic image are quantified using optical absorption measurements.
  • COM-based microspectrometry permits measurement of the Hb content of individual RBCs within an image. This can then be averaged over a plurality of imaged RBCs to estimate the mean corpuscular hemoglobin (MCH). The estimation of MCH, along with mean corpuscular volume (MCV) and red blood cell
  • RBC mean corpuscular hemoglobin concentration
  • Hgb concentration of hemoglobin in blood
  • Tsujita et al. measured the change of the absorbance spectrum within RBCs depending the presence of nitric oxide [K. Tsujita, T. Shiraishi, and K. Kakinuma,
  • Standard optical spectrometry measures the quantity of a light-absorbing analyte dispersed in a solution using Beer's law:
  • the cell in question causes no reflection, refraction, or scattering.
  • Hb p is the number of moles of Hb in the column above the pixel
  • V is the volume of the RBC portion directly above the pixel
  • d is the pixel side-length.
  • I p is the measured intensity of the pixel and I 0,p is the estimated background intensity, i.e., the intensity expected if no RBC was present.
  • the above equation is not sensitive to £, which is useful because path length is not known.
  • the [Hb] term has also been eliminated, which too is not directly measureable in a COM image. Equation (4) is rearranged, yielding
  • M Hb , d, and e are known constants.
  • I np , h,n P , P n , and N are outputs from computer vision described below.
  • Hb To increase the signal-to-noise ratio of the intensity measurements, it is preferable to illuminate Hb at a wavelength where its extinction coefficient is as high as possible. This gives maximum separation of I and Io, maximizing signal.
  • the absorbance maxima for Hb occur in the violet region of the visible spectrum (400-430 nm).
  • different varieties of Hb have different absorption spectra and maxima. Oxygenated hemoglobin (oxy-Hb) and deoxygenated hemoglobin (deoxy-Hb) both exist in blood.
  • the blood oxygenation of Hb i.e., the percentage of Hb in oxy-Hb form, can vary in the human body from 60% (venous blood) to -100% (arterial blood);.
  • the MCH CO M could depend on the oxygenation percentage and thus differ from the true MCH.
  • the illumination wavelength distribution can alter this coefficient. LEDs commonly have full-width-half-maxima of 5 nm and 10 nm, whereas the extinction peaks have full-width-half-maxima of -20 nm. As a result, using the extinction maximum is a reasonable approximation, even if the LED wavelength peak is off by 2 nm or so. Apart from improving the absorbance signal, a second advantage of selecting the extinction maximum is that the signal is less sensitive to small deviations in LED wavelength, since the slope at the peak is 0 (though the drop-off away from the peak is steep, so this effect is limited). A sample COM image obtained using 415 nm illumination is depicted in FIG. 2.
  • the ratio of measured mnb to true mnb can be calculated, where the measured mnb is calculated under the assumption of full oxygenation.
  • the m H b,measured is inversely proportional to e Hb , as seen in Equation (6), meaning that the mass measurement of any deoxy Hb will be off by a factor of e deoxy _ Hb /e oxy _ Hb , the ratio of true extinction to presumed extinction.
  • the mass fractions of oxy-Hb and deoxy-Hb should be added together but with the deoxy-Hb fraction multiplied by the ratio of the extinction coefficients:
  • StP instruments typically convert all Hb to carboxyhemoglobin (CO-Hb) or
  • methemoglobin after lysing the RBCs.
  • Hb needs to be converted within the cell, without damaging the membrane, during a reasonably short incubation time.
  • sodium nitrite NaN0 2
  • Sodium nitrite can pass through the RBC membrane, and it converts both oxy- and deoxy-Hb to met-Hb.
  • Met-Hb is hemoglobin whose iron ions have an oxidation state of 3+, instead of the normal 2+. Oxygen does not bind to met-Hb.
  • Met-Hb has an absorbance maximum at 405 nm with a 10-20% higher extinction coefficient compared to oxy-Hb [C.
  • Methemylation is therefore seen as a viable option for improving the reliability of COM- based microspectrometry. Using nitrite in large excess is posited to rapidly convert all of the Hb within cells and hold it at the maximum concentration longer than required for a COM
  • CVMCH .sampling the CV of e MCH , is given by: r. j e MCH nn tfmHb.RBC ⁇ nn CV mHb ,RBC
  • Beer's law relies on several assumptions that do not necessarily hold true in Hb microspectrometry. This can lead to an overall bias, cell-to-cell variation, or person-to-person variation in MCH calculations, the latter because blood from different persons can have different characteristics. Bias is correctable, and the number of RBCs counted is so large that the error of the estimate of the mean mn b ,RBc will be small, as described above. Person-to-person variation is therefore of the most concern, as this would weaken the correlation between MCH measured by COM and by current standard-of-practice (StP)
  • Beer's law assumes that there are no scattering or absorption events caused by materials in the blood film other than Hb itself. However, material inside or outside the RBC may also scatter or absorb. These events may lead to underestimation of the MCH, the effect is likely small, as Hb has much higher absorbance than any other blood/diluent component at the wavelengths in question [A. Airinei and A. Sadoveanu, "Spectrophotometric Analysis of the Blood Plasma," Rom. J. Biophys., vol. 16, no. 3, pp. 215-20, 2006][ M. De, S. Rana, H. Akpinar, O. R. Miranda, R. R. Arvizo, U. H. F. Bunz, and V. M. Rotello, "Sensing of proteins in human serum using conjugates of nanoparticles and green fluorescent protein,” Nat. Chem., vol. 1, no. September, pp. 461-5, 2009].
  • a drop of blood is mixed and incubated briefly with an appropriate diluent.
  • the blood mixture is injected into the specimen chamber, forming a thin film between the COM sensor and a transparent chamber lid. 3. Multiple images are acquired while light of a specific wavelength is transmitted through the chamber lid to illuminate the cells.
  • the images are processed and analyzed by a computer- vision algorithm to extract the MCH.
  • Diluent N which included NaN02, contained the following components dissolved in distilled water:
  • Diluent N diluent was NaN02, used to convert oxy-Hb and deoxy-Hb to met-Hb.
  • Diluents N and xN were identical except for the replacement in Diluent xN of NaN02 with a molar equivalent of NaCl.
  • the Brilliant Cresyl Blue stain was included for experiments that are beyond the scope of this research.
  • the diluent was designed to fulfill several functions to ensure that the cells maintained their health and form:
  • Anticoagulation prevents blood cells from aggregating irreversibly, which makes
  • Ethylenediaminetetraacetic acid was included as an anticoagulant.
  • the diluent was buffered at physiological pH (-7.4) using the HEPES buffer.
  • the diluent is chosen to achieve sphering of the red blood cells. It may be advantageous if the spacer (chamber height) is small enough ( ⁇ 3 ⁇ ) so that the resulting spherical red blood cells are compressed into a more-or-less cylindrical shape by the lowered chamber-lid, to provide an approximately uniform path length for the collimated light and to simplify the determination of cell volume.
  • the sphering agent can comprise inclusion of a surfactant such as sodium dodecyl sulfonate or hexadecyl trimethyl ammonium chloride. (See US patent application publication 2009/0258338).
  • Diluents were used to dilute a small blood sample at a 3: 1 diluen blood ratio. A thin film of this mixture was then formed by placing a drop between a glass slide and a glass coverslip. This film was examined using transmission microscopy to ensure that the cells were not damaged by the diluent. Cells using diluents N and xN diluents appeared very similar to cells in blood diluted using other formulations that met the requirements described above. In an acceptable diluent formulation, RBCs appear quite circular, with few having bulges or wrinkles. Also, almost all RBCs have light centers surrounded by a darker band. This indicates
  • the COM sensor used was an Omnivision OV8850, with 1.1 ?m square pixels. Bayer color filters were removed by reactive-ion etching.
  • a transparent chamber lid was used to form the thin blood film on the COM sensor.
  • a drop of blood:diluent mixture was placed on the sensor, and the chamber lid was gently lowered onto the sensor surface to a height of -3.5 ⁇ , with the height set using a spacer. This forced most of the blood mixture out the sides, leaving a small film of fluid remaining in the gap to be imaged.
  • the chamber height was not measured precisely. However, typical RBC have a maximum thickness of 2.6 ⁇ , so even if the chamber height varied by 20%, the chamber lid should not squash any RBCs. This height should cause the RBCs to lie flat though, as they have typical diameters 7.5 ⁇ [Y. Park, C. a Best, T. Auth, N. S. Gov, S. a Safran, G. Vietnamese, S. Suresh, and M. S. Feld, "Metabolic remodeling of the human red blood cell membrane," PNAS, vol. 107, no. 4, pp. 1289-94, Jan. 2010]. When the chamber lid was well seated, RBC stacking (rouleaux) was not observed.
  • the illuminator for the blood images consisted of two LEDs: a 405 nm LED (Mouser Electronics, 749-UV3TZ-405-15), a 415nm LED (Lumex, SSL-LXT046UV3C).
  • Experiment 1 Using Diluent N (nitrite-included) and 405 nm light, blood samples from 15 different individuals were each tested once on the StP. These 15 samples were tested between two and four times each using COM.
  • Experiment 2 The final six samples used in Experiment 1 were also tested using COM and Diluent xN (nitrite-free) with 415 nm illumination, with between one and four COM tests per sample. For these six samples, the Experiment 2 tests were performed prior to the
  • the background level calculated for each pixel was assigned to ⁇ , ⁇ in Equation (8).
  • a COM image was first thresholded to produce a binary mask. Objects greater than 1.5x or less than 0.5x the mean RBC size were eliminated. This eliminated the vast majority of noise, artifacts, RBC clusters, and occasional pixels from non-RBC objects. The remaining objects became the RBC segmentations for the MCH calculation. Step 3 took the intensity values for the pixels in each RBC
  • Equation (11) was used with Diluent N
  • Equation (9) was used for Diluent xN.
  • the chamber i.e., spacer
  • the described approach is not restricted to measurements of hemoglobin in red blood cells, but can be used to measure any substance that has a distinctive absorbance spectrum, in any cell or particle (so, for example in principle, for monitoring production of biopharmaceutical compounds by genetically engineered yeast cells).

Abstract

Among other things, a diluted sample is generated based on mixing a small sample of blood with a one or more diluents. A thin film of the diluted sample is formed on the surface of a contact optical microscopy sensor. Red blood cells within a portion of the thin film of the diluted sample are illuminated using light of a predetermined wavelength. One or more images of the diluted sample are acquired based on illuminating the red blood cells within the portion of the thin film of the diluted sample. The acquired one or more images of the diluted sample are then processed. The mean corpuscular hemoglobin in the red blood cells within the portion of the thin film of the diluted sample is determined based on processing the acquired images of the diluted sample.

Description

SAMPLE PROCESSING IMPROVEMENTS FOR QUANTITATIVE MICROSCOPY
PRIORITY CLAIMS AND RELATED APPLICATIONS
[0001] This application is entitled to the benefit of the filing date of United States patent application 62/131,164, filed March 10, 2015 and is a continuation-in-part of United States patent application 14/173,500, filed February 5, 2014, and is entitled to the benefit of the filing date of United States provisional patent application 61/761,467, filed February 6, 2013, and of United States provisional patent application 61/785,762, filed March 14, 2013. This application is also a continuation-in-part of United States patent application 14/314,743, filed June 25, 2014, and is entitled to the benefit of the filing date of United States patent application 61/839,735, filed June 26, 2013. Each of the patent applications identified above is incorporated here by reference in its entirety.
This application is also related to United States patent application 14/698,532, filed on April 28, 2015, which claims the benefit of United States patent application 12/913,639 filed on October 27, 2010 (now issued as United States Patent 9,041,790 on May 26, 2015), which claims the benefit of United States provisional patent application 61/255,781, filed on October 28, 2009 and is also related to United States patent application 14/710,046, filed on May 12, 2015, which claims benefit to United States patent application 13/095,175 filed on April 27, 2011 (now issued as United States Patent 9,075,225 on July 7, 2015), which claims the benefit of 12/913,639, filed on October 27, 2010 (now issued as United States Patent 9,041,790 on May 26, 2015), which claims the benefit of United States provisional patent application 61/255,781, filed on October 28, 2009. Each of the patent applications identified above is incorporated here by reference in its entirety.
FIELD
[0002] This specification generally describes technology related to sample processing for quantitative microscopy.
BACKGROUND [0003] Complete blood count (CBC) and other diagnostic tests that measure hemoglobin (Hb) content of blood typically measure Hb via a spectroscopic system or a subsystem after lysing red blood cells (RBCs).
SUMMARY
[0004] Traditional techniques that measure Hb content of blood often add bulk and complexity to the measurement processing, creating a number of disadvantages that are salient for point-of- care (POC) diagnostic devices. For instance, such techniques often require significant sample preparation, which is often inaccessible in resource-limited regions where POC diagnostic devices are often used. [0005] In general, in an aspect, a method for computing mean corpuscular hemoglobin can include: generating a diluted sample based on mixing a small sample of blood with one or more diluents; forming a thin film of the diluted sample on a surface of a contact optical microscopy sensor; illuminating red blood cells within a portion of the thin film of the diluted sample using light of a predetermined wavelength; acquiring one or more images of the diluted sample based on illuminating the red blood cells within the portion of the thin film of the diluted sample; processing the acquired one or more images of the diluted sample; and determining a value of mean corpuscular hemoglobin in the red blood cells within the portion of the thin film of the diluted sample based on processing the acquired images of the diluted sample.
[0006] One or more implementations may include the following optional features. For example, in some implementations, forming a thin film includes forming a thin film between a transparent chamber lid and the surface of the contact optical microscopy sensor.
[0007] In some implementations, forming a thin film between the lid and the contact optical microscopy sensor includes: placing the diluted sample on a surface of the contact optical microscopy sensor; and lowering the transparent chamber lid to a predetermined height determined by a spacer.
[0008] In some implementations, the size of the predetermined height is configured such that lowering of the transparent chamber lid onto the surface of the contact optical microscopy sensor (i) constrains the red blood cells to lie within a broadest dimension of the red blood cells parallel to the surface of the contact optical microscopy sensor, and (ii) does not result in structural damage to the red blood cells.
[0009] In some implementations, the one or more images of the diluted sample that are acquired include image features of at least one hundred red blood cells. [0010] In some implementations, the predetermined wavelength comprises a wavelength that corresponds to a wavelength within the absorbance band of a form of hemoglobin with the highest extinction coefficient of that form of hemoglobin.
[0011] In some implementations, processing the acquired images of the diluted sample includes: estimating a background pixel value for each pixel within the respective acquired images;
segmenting one or more regions within the respective acquired images that each contain exactly one red blood cell; and calculating the mean corpuscular hemoglobin based on the segmented one or more regions within the respective acquired images.
[0012] In some implementations, the generated diluted sample: has an isotonicity that is substantially equal to an isotonicity of red blood cells; has coagulation properties such that the generated diluted sample is less likely to coagulate compared to coagulation properties of red blood cells; and maintains a predetermined pH level of the generated diluted sample.
[0013] In some implementations, the acquired one or more images include at least a statistically significant number of the red blood cells in the diluted sample.
[0014] In some implementations, at least one of the one or more diluents comprises a nitrite. [0015] In some implementations, generating a diluted sample comprises generating a diluted sample based on mixing the sample of blood with a diluent such that the mixing results in sphering of the red blood cells within the diluted sample.
[0016] In general, in an aspect, a method for computing a mean amount of a measured analyte within a fluid sample can include: forming a thin film of a fluid sample on a surface of a contact optical microscopy sensor, the fluid sample comprising particulate matter that includes an analyte to be measured, the analyte having a distinctive absorption spectrum; illuminating at least a portion of the thin film of the fluid sample using white light of a predetermined wavelength; acquiring one or more images of the fluid sample based on illuminating at least a portion of the thin film of the fluid sample using white light of a predetermined; wavelength; processing the acquired one or more images of the fluid sample; and determining a value of a mean amount of the analyte based on processing the one or more images of the fluid sample.
[0017] In some implementations, forming a thin film includes forming a thin film between a transparent chamber lid and the contact optical microscopy sensor. [0018] In some implementations, forming a thin film between the lid and the surface of the contact optical microscopy sensor includes: placing the fluid sample on a surface of the contact optical microscopy sensor and lowering the transparent chamber lid to a predetermined height determined by a spacer.
[0019] In some implementations, the size of the predetermined height is configured such that lowering of the transparent chamber lid onto the surface of the contact optical microscopy sensor (i) constrains the particulate matter of the sample fluid to lie within a broadest dimension of the particular matter to the surface of the contact optical microscopy sensor, and (ii) does not result in structural damage to the particulate matter of the sample fluid.
[0020] In some implementations, processing the one or more acquired images includes:
estimating a background pixel value for each pixel within the respective one or more acquired images; segmenting one or more regions within the respective acquired images that each contain exactly one particle; and calculating the mean amount of the analyte based on the segmented one or more regions within the respective acquired images.
[0021] In some implementations, forming a thin film includes: placing the fluid sample on the surface of the contact optical microscopy sensor; and enabling the thin film of the fluid sample formed on a surface of a contact optical microscopy sensor to settle.
These, and other aspects, features, implementations, and advantages may be expressed as methods, apparatus, systems, components, compositions, software products, methods of doing business, and in other ways. [0022] These and other aspects, features, implementations, and advantages will become apparent from the following description and from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS [0023] FIG. 1 is graph of hemoglobin absorption spectra. [0024] FIG. 2 is a contact optical microscopy image of a blood cell.
[0025] In the drawings, like reference numbers represent corresponding parts throughout.
DETAILED DESCRIPTION
[0026] In some examples, the bulk and complexity of the conventional CBC process can be overcome with the use of contact optical microscopy (COM)-based microspectrometry. In some instances, such techniques can also be implemented with optical lens microscopes. In COM- based microspectrometry, molecules in individual pixels and regions in a microscopic image are quantified using optical absorption measurements. COM-based microspectrometry permits measurement of the Hb content of individual RBCs within an image. This can then be averaged over a plurality of imaged RBCs to estimate the mean corpuscular hemoglobin (MCH). The estimation of MCH, along with mean corpuscular volume (MCV) and red blood cell
concentration (RBC), both of which can be determined from the microscopy image, mean corpuscular hemoglobin concentration (MCHC) and concentration of hemoglobin in blood (Hgb), additional elements of the CBC, can then be derived. [0027] To calculate the MCH from a COM image, microspectrometry must be used to initially quantify Hb content. Microspectrometry within lens-based microscopy has existed for many decades and has been performed previously on RBCs. In 1960, Sondhaus & Thorell published a study in which the Hb absorbance spectra from sub-areas of RBCs were examined, exploring the correlation of RBC maturity and Hb and free-iron content [C. A. Sondhaus and B. Thorell, "Micro spectrophotometric Determination of Nonheme Iron in Maturing Erythroblasts and its Relationship to the Endocellular Hemoglobin Formation," Blood, vol. 16, no. 3, pp. 1285-97, I960]. Tsujita et al. measured the change of the absorbance spectrum within RBCs depending the presence of nitric oxide [K. Tsujita, T. Shiraishi, and K. Kakinuma,
"Microspectrophotometry of nitric oxide-dependent changes in hemoglobin in single red blood cells incubated with stimulated macrophages," J. Biochem., vol. 122, no. 2, pp. 264-70, Aug. 1997]. Meletis et al. attempted to measure MCH using lens-based transmission
microspectrometry [J. Meletis, X. Yataganas, G. Eliopoulos, J. Panourgais, D. Loukopoulos, and P. Fessas, "Hemoglobin Content of Single Erythrocytes from Fetuses with Parents Having Heterozyhous β-Thalassemia," Acta Haematol., vol. 73, pp. 16-21, 1985]. Blood was spread on a glass slide, and 50-100 RBCs in each sample were measured by illuminating them with 415 nm light, dividing the full area of each RBC into 0.5 μηι pixels, and measuring absorbance at each pixel. This process was slow (60-90 minutes per test), and results, though well correlated with those obtained using ordinary instruments based on spectroscopy of lysed blood (R2 = 0.87) were unacceptably variable (coefficient of variation, CV = 28%). [0028] Some of this variability is due to the small number of RBC within a standard high magnification field of view. COM, however, yields high magnification over a very large field of view that can include large numbers of RBCs. In addition, lens-based microspectrometry for quantification of absorbing molecules is also sensitive to focal plane alignment relative to the RBCs, since light transmitting through Hb that is outside the focal plane may not be collected. Thus, for example, the depth of focus of the objective lens used by Meletis et al. was <0.5 μπι, which is much thinner than an RBC (typically 1.1 μιη thick at the center and 2.6 μιη thick at the torus-shaped outer band [K. G. Engstrom and E. Lofvenberg, "Treatment of Myeloproliferative Disorders With Hydroxyurea: Effects on Red Blood Cell Geometry and Deformability," Blood, vol. 91, no. 10, pp. 3986-3991, 1998]), meaning parts of every RBC measured were out of focus, so that part of the Hb signal can be blurred outside the cell borders and lost. COM, on the other hand, has no focal plane - COM produces very little blurring of objects less than a few microns from the imaging surface - so can outperform standard microspectrometry for MCH
measurement.
[0029] Standard optical spectrometry measures the quantity of a light-absorbing analyte dispersed in a solution using Beer's law:
I
- = 10A(-e C ) (1) lo
[0030] where ¾ is the incident light intensity, I is the transmitted light intensity, e is the extinction coefficient (molar absorptivity) of the absorber (Hb in this case) at the incident wavelength, C is the molar concentration of the absorber in the solution, and £ is the path length through the solution. Extinction is caused by light either being scattered or lost to true
absorption, where the energy is converted to another form. Microspectrometry relies on Beer's law, but applies it to images of microscale objects to calculate the absorber's concentration within that object. [0031] The following derivation of the relationship between MCH and Beer's law depends on the following simplifying assumptions:
1. The cell in question causes no reflection, refraction, or scattering.
2. Only one Hb form is present, meaning e is known. 3. There is uniform [Hb] concentration inside the RBC and negligible [Hb] outside the
RBC.
4. Within a given pixel, the RBC thickness, £, is uniform. [0032] The validity of these assumptions is addressed below. [0033] For each pixel covered by an RBC, the following two equations are defined:
C = [Hb] = (2)
V = d2 * £ (3)
[0034] where Hbp is the number of moles of Hb in the column above the pixel, V is the volume of the RBC portion directly above the pixel, and d is the pixel side-length. The 2nd equation assumes that £ is constant over the entire pixel. These two definitions are substituted into Beer's law to yield: i = io" (-£(¾)f) (4)
[0035] where Ip is the measured intensity of the pixel and I0,p is the estimated background intensity, i.e., the intensity expected if no RBC was present. The above equation is not sensitive to £, which is useful because path length is not known. The [Hb] term has also been eliminated, which too is not directly measureable in a COM image. Equation (4) is rearranged, yielding
[0036] Converting moles of Hb to mass of Hb via a simple unit conversion, mHb p = MHb * Hbp, where MHb is the molar mass, and solving for mHb p yields the mass of Hb above the pixel.
M Hb
mHb,p (6) [0037] This is summed over all the pixels in the RBC, yielding
[0038] where P is the total number of pixels covered by the RBC. Once mHb RBC is calculated for N RBCs in the image, the mean is taken to yield the MCH:
[0039] In the MCH equation above, MHb, d, and e are known constants. Inp, h,nP, Pn, and N and are outputs from computer vision described below.
[0040] To increase the signal-to-noise ratio of the intensity measurements, it is preferable to illuminate Hb at a wavelength where its extinction coefficient is as high as possible. This gives maximum separation of I and Io, maximizing signal. The absorbance maxima for Hb occur in the violet region of the visible spectrum (400-430 nm). [0041] As depicted in FIG. 1, different varieties of Hb have different absorption spectra and maxima. Oxygenated hemoglobin (oxy-Hb) and deoxygenated hemoglobin (deoxy-Hb) both exist in blood. The blood oxygenation of Hb, i.e., the percentage of Hb in oxy-Hb form, can vary in the human body from 60% (venous blood) to -100% (arterial blood);. The vast majority of the remaining Hb exists in deoxy-Hb form, except in cases of blood poisoning. The MCHCOM could depend on the oxygenation percentage and thus differ from the true MCH.
[0042] Though oxy- and deoxy-Hb have different absorbance profiles, it was suspected that in a real POC test, the vast majority of the Hb would be oxygenated while the blood droplet waited on a finger. If it is assumed that Hb is fully oxygenated, then eQxy-Hb has a maximum value of 5.243 *105 cm_1M_1, occurring at 415 nm. Substituting this value into Equation (8), as well as Mfjb = 64 500 g/mol [S. Prahl, "Optical Absorption of Hemoglobin," Oregon Medical Laser Center, 1999. [Online]. Available: http://omlc.org/spectra/hemoglobin/. [Accessed: 15-Feb- 2013].] and d = 1.1 μιη (the pixel size of the COM sensor used in this research) yields:
[0043] Note that the illumination wavelength distribution can alter this coefficient. LEDs commonly have full-width-half-maxima of 5 nm and 10 nm, whereas the extinction peaks have full-width-half-maxima of -20 nm. As a result, using the extinction maximum is a reasonable approximation, even if the LED wavelength peak is off by 2 nm or so. Apart from improving the absorbance signal, a second advantage of selecting the extinction maximum is that the signal is less sensitive to small deviations in LED wavelength, since the slope at the peak is 0 (though the drop-off away from the peak is steep, so this effect is limited). A sample COM image obtained using 415 nm illumination is depicted in FIG. 2.
[0044] As depicted in FIG. 2, violet illumination results in good contrast for RBCs in
comparison to platelets and WBCs. Contrast also aids in machine-based RBC segmentation and counting, since RBCs are easily distinguished from other objects in the image.
[0045] It is assumed in the above analysis that all Hb is converted to oxy-Hb. If this is not the case, the MCH correlation is likely to be poor. However, there are different ways to address this potential problem. [0046] One solution is to illuminate the blood at the maximum oxy/deoxy-Hb isosbestic point, 422 nm. Isosbestic points are wavelengths where both forms of Hb have equal absorbance.
However, LEDs are not easily found at this wavelength. To predict the effect of off-isosbestic illumination, the ratio of measured mnb to true mnb can be calculated, where the measured mnb is calculated under the assumption of full oxygenation. The mHb,measured is inversely proportional to eHb, as seen in Equation (6), meaning that the mass measurement of any deoxy Hb will be off by a factor of edeoxy_Hb/eoxy_Hb, the ratio of true extinction to presumed extinction. To calculate the mass ratio, the mass fractions of oxy-Hb and deoxy-Hb should be added together but with the deoxy-Hb fraction multiplied by the ratio of the extinction coefficients:
[0047] where/is the oxy-Hb fraction, set to 0.6 in the worst case. Converting the mass ratio to a percent difference is straightforward, and the result is obtained that if the illumination is even 1 nm off the isosbestic point in either direction, the resulting Hb mass measurement will off be up to 4%. This is due to the sharply opposing slopes of the oxy/deoxy-Hb absorbance. A wavelength tolerance of <1 nm may be achievable with appropriate illumination sources and optical filters, but a simpler solution is available, as described below.
[0048] There are other isosbestic points with less severe differences in slopes, such as 390 nm, but these have much lower absorbance, reducing RBC contrast. They may be useful, but would be more difficult from a computer- vision perspective.
[0049] Another possibility is to chemically convert both oxy-Hb and deoxy-Hb to a third, single form. StP instruments typically convert all Hb to carboxyhemoglobin (CO-Hb) or
methemoglobin (met-Hb) after lysing the RBCs. For Hb microspectrometry, Hb needs to be converted within the cell, without damaging the membrane, during a reasonably short incubation time. Fortunately, sodium nitrite (NaN02) is a suitable conversion agent. Sodium nitrite can pass through the RBC membrane, and it converts both oxy- and deoxy-Hb to met-Hb. Met-Hb is hemoglobin whose iron ions have an oxidation state of 3+, instead of the normal 2+. Oxygen does not bind to met-Hb. Met-Hb has an absorbance maximum at 405 nm with a 10-20% higher extinction coefficient compared to oxy-Hb [C. Donadee, N. J. H. Raat, T. Kanias, J. Tejero, J. S. Lee, E. E. Kelley, X. Zhao, C. Liu, H. Reynolds, I. Azarov, S. Frizzell, E. M. Meyer, A. D. Donnenberg, L. Qu, D. Triulzi, D. B. Kim-Shapiro, and M. T. Gladwin, "Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion," Circulation, vol. 124, no. 4, pp. 465-76, Jul. 2011]. Assuming the maximum extinction coefficient for met-Hb is 15% higher than that of oxyHb, the MCH equation becomes:
[0050] Blood and Power [30] showed that conversion of both oxy-Hb and deoxy-Hb to met-Hb in live RBCs is also relatively rapid, particularly when both oxy-Hb and deoxy-Hb species exist in the blood: maximum [met-Hb] was reached after 20 minutes with an initial 1: 12 nitrite:heme ratio (heme being the oxygen binding subunit of Hb, of which there are four per molecule), and was followed by [metHb] decreasing slowly due to methemoglobin reductase activity and reaction with nitric oxide, the byproduct of methemylation of deoxy-Hb [A. B. Blood and G. G. Power, "In vitro and in vivo kinetic handling of nitrite in blood: effects of varying hemoglobin oxygen saturation," Am. J. Physiol. Heart Circ. Physiol, vol. 293, pp. H1508-17, Sep. 2007]. [0051] At normal venous blood oxygenation of 60%, the worst-case scenario for capillary blood, approximately 100% conversion to met-Hb is achieved after 60 seconds (using purified Hb) [R. Grubina, Z. Huang, S. Shiva, M. S. Joshi, I. Azarov, S. Basu, L. a Ringwood, A. Jiang, N. Hogg, D. B. Kim-Shapiro, and M. T. Gladwin, "Concerted nitric oxide formation and release from the simultaneous reactions of nitrite with deoxy- and oxyhemoglobin," J. Biol. Chem. , vol. 282, no. 17, pp. 12916-27, Apr. 2007]. Therefore, conversion efficiency and rate is not likely to be an issue.
[0052] Methemylation is therefore seen as a viable option for improving the reliability of COM- based microspectrometry. Using nitrite in large excess is posited to rapidly convert all of the Hb within cells and hold it at the maximum concentration longer than required for a COM
experiment.
[0053] In order to obtain consistently precise estimates of the MCH, it must be ensured that a sufficient number of countable RBCs are present in any COM image.
[0054] The standard error of the mean of measurements drawn from a Gaussian distribution is
[0055] where σ is the standard deviation and N is the number of measurements. Assuming that niHb,RBc follows a Gaussian distribution between RBCs, this equation can be applied to the MCH measurement, where N is the number of RBCs sampled for the calculation of the MCH. Thus, "CVMCH .sampling ", the CV of eMCH, is given by: r.j eMCH nn tfmHb.RBC Λ nn CVmHb ,RBC
C M MCLHH. ssaammopllimnge = 7 jyΤi7CΓHΓΤ * 100 = MCH Λ/—Ν * 100 = Λ/—Ν (13)
[0056] where amHb RBC is the standard deviation of the mHb,RBc measurements (MCH is the mean of these measurements). Solving for N yields:
N = CVmHb'RBC (14)
\CVMCH,sam ling/
[0057] Assuming a worst-case CVmHb,RBc of 50% (which would be highly clinically abnormal), to achieve an ideal value of CVMCH,samPiing < 1%, making it essentially negligible with respect to a target CVMCH of 5%, at least 2000 RBCs need to be sampled, as calculated by substituting these two values into Equation (14). [0058] At roughly 50 pixels per RBC and 8 million pixels in the field-of-view of an 8 megapixel sensor with Ι.ΐμπι pixel pitch, well over 10 000 RBCs can be included the field of view while still leaving most of the area as background (which allows for more straightforward calculation of t).
[0059] Beer's law relies on several assumptions that do not necessarily hold true in Hb microspectrometry. This can lead to an overall bias, cell-to-cell variation, or person-to-person variation in MCH calculations, the latter because blood from different persons can have different characteristics. Bias is correctable, and the number of RBCs counted is so large that the error of the estimate of the mean mnb,RBc will be small, as described above. Person-to-person variation is therefore of the most concern, as this would weaken the correlation between MCH measured by COM and by current standard-of-practice (StP)
[0060] Beer's law assumes that there are no scattering or absorption events caused by materials in the blood film other than Hb itself. However, material inside or outside the RBC may also scatter or absorb. These events may lead to underestimation of the MCH, the effect is likely small, as Hb has much higher absorbance than any other blood/diluent component at the wavelengths in question [A. Airinei and A. Sadoveanu, "Spectrophotometric Analysis of the Blood Plasma," Rom. J. Biophys., vol. 16, no. 3, pp. 215-20, 2006][ M. De, S. Rana, H. Akpinar, O. R. Miranda, R. R. Arvizo, U. H. F. Bunz, and V. M. Rotello, "Sensing of proteins in human serum using conjugates of nanoparticles and green fluorescent protein," Nat. Chem., vol. 1, no. September, pp. 461-5, 2009].
[0061] Reference physiological "free" [Hb] (Hb concentration in the plasma) is as high as 5 μΜ [N. Na, J. Ouyang, Y. E. C. Taes, and J. R. Delanghe, "Serum free hemoglobin concentrations in healthy individuals are related to haptoglobin type," Clin. Chem., vol. 51, no. 9, pp. 1754-5, Sep. 2005], while reference MCHC values are as low as 5000 μΜ [N. Beck, Diagnostic Hematology. London: Springer London, 2009], three orders of magnitude higher than the image background. Thus free plasma is normally negligible in the MCH calculation. The assumption of negligible [Hb] outside RBCs may be false if significant hemolysis is present. Free [Hb] can rise to 10 μΜ during severe sepsis [M. Adamzik, T. Hamburger, F. Petrat, J. Peters, H. de Groot, and M.
Hartmann, "Free hemoglobin concentration in severe sepsis: methods of measurement and prediction of outcome," Crit. Care, vol. 16, no. 4, Jul. 2012] or 25 μΜ during a sickle cell anemia crisis [D. J. Schaer, P. W. Buehler, A. I. Alayash, J. D. Belcher, and G. M. Vercellotti, "Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins," Blood, vol. 121, no. 8, pp. 1276-84, Feb. 2013]. This, however, is still at least two orders of magnitude smaller than the lowest levels of MCHC, so it is still negligible.
[0062] The general method for measuring the MCH on a drop blood using COM is as follows:
1. A drop of blood is mixed and incubated briefly with an appropriate diluent.
2. The blood mixture is injected into the specimen chamber, forming a thin film between the COM sensor and a transparent chamber lid. 3. Multiple images are acquired while light of a specific wavelength is transmitted through the chamber lid to illuminate the cells.
4. The images are processed and analyzed by a computer- vision algorithm to extract the MCH.
5. The specimen chamber is cleaned. [0063] To test the central hypothesis, several blood samples from different individuals were tested on both a single COM device and an StP machine. The data were compared using regression analysis to determine suitable correlation parameters, the coefficient of determination (R2), and the CV of the residuals.
[0064] Two diluents were prepared for the experiments, to be mixed with blood at a 3: 1 diluen blood ratio. Diluent N, which included NaN02, contained the following components dissolved in distilled water:
1. 112.3 mM NaN02
2. 6.5 mM Brilliant Cresyl Blue stain (Sigma, 860867)
3. 21.3 mM Disodium EDTA (EM Science, EX0539-1) 4. 5.87 mM HEPES (Sigma, H4034)
5. 5.57 mM KCl
6. 7.36 mM NaCl [0065] Diluent xN, which excluded NaN02, contained the following components dissolved in distilled water:
1. 6.5 mM Brilliant Cresyl Blue stain (1% w/w)
2. 21.3 mM Disodium dihydrate EDTA 3. 5.87 mM HEPES
4. 5.57 mM KCl
5. 118.6 mM NaCl
[0066] The key component of Diluent N diluent was NaN02, used to convert oxy-Hb and deoxy-Hb to met-Hb. Diluents N and xN were identical except for the replacement in Diluent xN of NaN02 with a molar equivalent of NaCl. The Brilliant Cresyl Blue stain was included for experiments that are beyond the scope of this research. The diluent was designed to fulfill several functions to ensure that the cells maintained their health and form:
1. Isotonicity, to maintain cell shape and health, was achieved using appropriate
concentrations of NaCl, KC1, and NaN02 in the diluents. 2. Anticoagulation prevents blood cells from aggregating irreversibly, which makes
counting them difficult. Ethylenediaminetetraacetic acid (EDTA) was included as an anticoagulant.
3. The diluent was buffered at physiological pH (-7.4) using the HEPES buffer.
[0067] In some cases the diluent is chosen to achieve sphering of the red blood cells. It may be advantageous if the spacer (chamber height) is small enough (<3 μιη) so that the resulting spherical red blood cells are compressed into a more-or-less cylindrical shape by the lowered chamber-lid, to provide an approximately uniform path length for the collimated light and to simplify the determination of cell volume. The sphering agent can comprise inclusion of a surfactant such as sodium dodecyl sulfonate or hexadecyl trimethyl ammonium chloride. (See US patent application publication 2009/0258338).
[0068] Diluents were used to dilute a small blood sample at a 3: 1 diluen blood ratio. A thin film of this mixture was then formed by placing a drop between a glass slide and a glass coverslip. This film was examined using transmission microscopy to ensure that the cells were not damaged by the diluent. Cells using diluents N and xN diluents appeared very similar to cells in blood diluted using other formulations that met the requirements described above. In an acceptable diluent formulation, RBCs appear quite circular, with few having bulges or wrinkles. Also, almost all RBCs have light centers surrounded by a darker band. This indicates
biconcavity, since the thinner cell center absorbs less light. Further, lack of coagulation is indicated by the individual cells appearing fairly evenly distributed and without stacking.
[0069] The COM sensor used was an Omnivision OV8850, with 1.1 ?m square pixels. Bayer color filters were removed by reactive-ion etching.
[0070] A transparent chamber lid was used to form the thin blood film on the COM sensor. A drop of blood:diluent mixture was placed on the sensor, and the chamber lid was gently lowered onto the sensor surface to a height of -3.5 μπι, with the height set using a spacer. This forced most of the blood mixture out the sides, leaving a small film of fluid remaining in the gap to be imaged.
[0071] The chamber height was not measured precisely. However, typical RBC have a maximum thickness of 2.6 μπι, so even if the chamber height varied by 20%, the chamber lid should not squash any RBCs. This height should cause the RBCs to lie flat though, as they have typical diameters 7.5 μιη [Y. Park, C. a Best, T. Auth, N. S. Gov, S. a Safran, G. Popescu, S. Suresh, and M. S. Feld, "Metabolic remodeling of the human red blood cell membrane," PNAS, vol. 107, no. 4, pp. 1289-94, Jan. 2010]. When the chamber lid was well seated, RBC stacking (rouleaux) was not observed.
[0072] The illuminator for the blood images consisted of two LEDs: a 405 nm LED (Mouser Electronics, 749-UV3TZ-405-15), a 415nm LED (Lumex, SSL-LXT046UV3C).
[0073] Experiment 1 : Using Diluent N (nitrite-included) and 405 nm light, blood samples from 15 different individuals were each tested once on the StP. These 15 samples were tested between two and four times each using COM.
[0074] Experiment 2: The final six samples used in Experiment 1 were also tested using COM and Diluent xN (nitrite-free) with 415 nm illumination, with between one and four COM tests per sample. For these six samples, the Experiment 2 tests were performed prior to the
Experiment 1 tests because the former are likely to be more sensitive to oxygen contamination. [0075] For the MCH calculations, all images were processed identically. Four violet images were averaged together to reduce noise, and the 20-frame averaged 6 ms-exposure darkframe was subtracted, yielding a single master image. The computer- vision algorithm consisted of three steps: 1. Estimate the background value for every pixel in the image
2. Segment regions containing exactly one RBC (image segmentation)
3. Calculate the MCH using Equation (8)
[0076] In each RBC segmentation, the background level calculated for each pixel was assigned to ΙΟ,ηρ in Equation (8). For the image segmentation of step 2, a COM image was first thresholded to produce a binary mask. Objects greater than 1.5x or less than 0.5x the mean RBC size were eliminated. This eliminated the vast majority of noise, artifacts, RBC clusters, and occasional pixels from non-RBC objects. The remaining objects became the RBC segmentations for the MCH calculation. Step 3 took the intensity values for the pixels in each RBC
segmentation and scanned over them, applying the MCH equations described above. Equation (11) was used with Diluent N, and Equation (9) was used for Diluent xN.
[0077] Data acquisition and analysis in comparison with StP showed that the results of the Diluent xN tests and the corresponding Diluent N tests were somewhat similar. Both met the CVMCH, target requirement, with similar CVMCH's of 2.27% and 3.38% respectively. For these subjects, the correlation between COM and StP measurements was very strong for both Diluent N and xN, with R2 values of 0.96 and 0.98 respectively.
[0078] Variation in MCHCOM measurements depends on several factors, one of which is RBC shape, presumably due to violations of the Beer's law assumptions discussed above. Thus measurements of MCH, as well as of MCV, can be improved by converting the RBCs from dicoid to spherical shape [Kim YR, Ornstein L: Isovolumetric sphering of erythrocytes for more accurate and precise cell volume measurement by flow cytometry. Cytometry 4:419, 1983] and various US patents [e.g., Fan et al., 1997 US 5,633,167 and patents cited therein]. If the chamber (i.e., spacer) height is less than the diameter of the sphered RBCs, they will be compressed into cylinders of uniform thickness. [0079] Other implementations are within the scope of the following claims. For example, the described approach is not restricted to measurements of hemoglobin in red blood cells, but can be used to measure any substance that has a distinctive absorbance spectrum, in any cell or particle (so, for example in principle, for monitoring production of biopharmaceutical compounds by genetically engineered yeast cells).
[0080] What is claimed is:

Claims

1. A method comprising:
generating a diluted sample, the generating comprising mixing a small sample of blood with one or more diluents;
5 forming a thin film of the diluted sample on a surface of a contact optical microscopy sensor;
illuminating red blood cells within a portion of the thin film of the diluted sample using light of a predetermined wavelength;
acquiring one or more images of the diluted sample based on the illuminating of the red o blood cells within the portion of the thin film of the diluted sample;;
processing the acquired one or more images of the diluted sample; and
determining the mean corpuscular hemoglobin in the red blood cells within the portion of the thin film of the diluted sample based on the processing of the acquired images of the diluted sample.
5
2. The method of claim 1, wherein forming a thin film comprises forming a thin film between a transparent chamber lid and the surface of the contact optical microscopy sensor.
3. The method of claim 2, wherein forming a thin film between the lid and the surface of the0 contact optical microscopy sensor comprises:
placing the diluted sample on the surface of the contact optical microscopy sensor; and lowering the transparent chamber lid to a predetermined height determined by a spacer.
4. The method of claim 3, wherein the magnitude of the predetermined height is configured5 such that lowering of the transparent chamber lid onto the surface of the contact optical
microscopy sensor (i) constrains the red blood cells to lie within a broadest dimension of the red blood cells parallel to the surface of the contact optical microscopy sensor, and (ii) does not result in structural damage to the red blood cells. 0 5. The method of any one of claims 1 to 4, wherein the one or more images of the diluted sample that are acquired include image features of at least one hundred red blood cells.
6. The method of any one of claims 1 to 5, wherein the predetermined wavelength comprises a wavelength that corresponds to a wavelength within the absorbance band of a form of hemoglobin with the highest extinction coefficient of that form of hemoglobin.
7. The method of any one of claims 1 to 6, wherein processing the acquired images of the diluted sample comprises:
estimating a background pixel value for each pixel within each of the respective acquired images;
segmenting one or more regions within the respective acquired images that each contain exactly one red blood cell; and
calculating the mean corpuscular hemoglobin based on the one or more segmented regions within the respective acquired images.
8. The method of any one of claims 1 to 7, wherein the generated diluted sample:
has an isotonicity that is substantially equal to an isotonicity of red blood cells;
has coagulation properties such that the generated diluted sample is less likely to coagulate compared to coagulation properties of red blood cells; and
maintains a predetermined pH level of the generated diluted sample.
9. The method of any one of claims 1 to 8, wherein the acquired one or more images include at least a statistically significant number of the red blood cells in the diluted sample.
10. The method of any one of claims 1 to 9, wherein at least one of the one or more diluents comprises a nitrite.
11. The method of any one of claims 1 to 10, wherein generating a diluted sample comprises generating a diluted sample based on mixing the sample of blood with a diluent such that the mixing results in sphering of the red blood cells within the diluted sample.
12. A method comprising:
forming a thin film of a fluid sample on a surface of a contact optical microscopy sensor, the fluid sample comprising particulate matter that includes an analyte to be measured, the analyte having a distinctive absorption spectrum;
illuminating at least a portion of the thin film of the fluid sample using light of a predetermined wavelength;
acquiring one or more images of the fluid sample based on the illuminating of at least a portion of the thin film of the fluid sample using the light of a predetermined; wavelength; processing the acquired one or more images of the fluid sample; and
determining a mean amount of the analyte based on the processing of the one or more images of the fluid sample.
13. The method of claim 12, wherein forming a thin film comprises forming a thin film between a transparent chamber lid and the surface of the contact optical microscopy sensor.
14. The method of claim 13, wherein forming a thin film between the lid and the surface of the contact optical microscopy sensor comprises:
placing the fluid sample on the surface of the contact optical microscopy sensor and lowering the transparent chamber lid to a predetermined height determined by a spacer.
15. The method of claim 14, wherein the magnitude of the predetermined height is configured such that lowering of the transparent chamber lid onto the surface of the contact optical microscopy sensor (i) constrains the particulate matter of the sample fluid to lie within a broadest dimension of the particular matter to the surface of the contact optical microscopy sensor, and (ii) does not result in structural damage to the particulate matter of the sample fluid.
16. The method of any one of claims 12 to 15, wherein processing the one or more acquired images comprises:
estimating a background pixel value for each pixel within each of the respective one or more acquired images; segmenting one or more regions within the respective acquired images that each contain exactly one particle; and
calculating the mean amount of the analyte based on the segmented one or more regions within the respective acquired images.
17. The method of claim 13, wherein forming a thin film comprises:
placing the fluid sample on the surface of the contact optical microscopy sensor; and enabling the thin film of the fluid sample formed on a surface of a contact optical microscopy sensor to settle.
EP16760984.1A 2015-03-10 2016-03-10 Sample processing improvements for quantitative microscopy Withdrawn EP3268737A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131164P 2015-03-10 2015-03-10
PCT/CA2016/050263 WO2016141487A1 (en) 2015-03-10 2016-03-10 Sample processing improvements for quantitative microscopy

Publications (2)

Publication Number Publication Date
EP3268737A1 true EP3268737A1 (en) 2018-01-17
EP3268737A4 EP3268737A4 (en) 2018-11-14

Family

ID=56879753

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16760984.1A Withdrawn EP3268737A4 (en) 2015-03-10 2016-03-10 Sample processing improvements for quantitative microscopy

Country Status (2)

Country Link
EP (1) EP3268737A4 (en)
WO (1) WO2016141487A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9989750B2 (en) 2013-06-26 2018-06-05 Alentic Microscience Inc. Sample processing improvements for microscopy
US10114203B2 (en) 2009-10-28 2018-10-30 Alentic Microscience Inc. Microscopy imaging
US10502666B2 (en) 2013-02-06 2019-12-10 Alentic Microscience Inc. Sample processing improvements for quantitative microscopy
US10620234B2 (en) 2009-10-28 2020-04-14 Alentic Microscience Inc. Microscopy imaging

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114778418B (en) * 2022-06-17 2022-09-27 深圳安侣医学科技有限公司 Hemoglobin analysis method and system based on micro-amplification digital image

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284771A (en) 1991-12-05 1994-02-08 Miles Inc. Reagent compositions and their use in sphering cells
CN101561443B (en) * 2008-04-15 2013-08-21 深圳迈瑞生物医疗电子股份有限公司 Five-classification leucocyte simulacrum particle, method for preparing same, and quality control substance and calibration substance containing same
US20140152801A1 (en) 2009-10-28 2014-06-05 Alentic Microscience Inc. Detecting and Using Light Representative of a Sample
CA2778725C (en) * 2009-10-28 2019-04-30 Alentic Microscience Inc. Microscopy imaging
EP2519820B1 (en) 2009-12-31 2013-11-06 Abbott Point Of Care, Inc. Method and apparatus for determining mean cell volume of red blood cells
WO2014205576A1 (en) 2013-06-26 2014-12-31 Alentic Microscience Inc. Sample processing improvements for microscopy

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10866395B2 (en) 2009-10-28 2020-12-15 Alentic Microscience Inc. Microscopy imaging
US10114203B2 (en) 2009-10-28 2018-10-30 Alentic Microscience Inc. Microscopy imaging
US10345564B2 (en) 2009-10-28 2019-07-09 Alentic Microscience Inc. Microscopy imaging
US11947096B2 (en) 2009-10-28 2024-04-02 Alentic Microscience Inc. Microscopy imaging
US11635447B2 (en) 2009-10-28 2023-04-25 Alentic Microscience Inc. Microscopy imaging
US10520711B2 (en) 2009-10-28 2019-12-31 Alentic Microscience Inc. Microscopy imaging
US10620234B2 (en) 2009-10-28 2020-04-14 Alentic Microscience Inc. Microscopy imaging
US11294160B2 (en) 2009-10-28 2022-04-05 Alentic Microscience Inc. Microscopy imaging
US10900999B2 (en) 2009-10-28 2021-01-26 Alentic Microscience Inc. Microscopy imaging
US10502666B2 (en) 2013-02-06 2019-12-10 Alentic Microscience Inc. Sample processing improvements for quantitative microscopy
US10768078B2 (en) 2013-02-06 2020-09-08 Alentic Microscience Inc. Sample processing improvements for quantitative microscopy
US11598699B2 (en) 2013-02-06 2023-03-07 Alentic Microscience Inc. Sample processing improvements for quantitative microscopy
US10809512B2 (en) 2013-06-26 2020-10-20 Alentic Microscience Inc. Sample processing improvements for microscopy
US10746979B2 (en) 2013-06-26 2020-08-18 Alentic Microscience Inc. Sample processing improvements for microscopy
US9989750B2 (en) 2013-06-26 2018-06-05 Alentic Microscience Inc. Sample processing improvements for microscopy
US11874452B2 (en) 2013-06-26 2024-01-16 Alentic Microscience Inc. Sample processing improvements for microscopy
US10459213B2 (en) 2013-06-26 2019-10-29 Alentic Microscience Inc. Sample processing improvements for microscopy

Also Published As

Publication number Publication date
EP3268737A4 (en) 2018-11-14
WO2016141487A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
US11598699B2 (en) Sample processing improvements for quantitative microscopy
EP3268737A1 (en) Sample processing improvements for quantitative microscopy
CN105408745B (en) The method and apparatus for determining the parameter based on hemoglobin in uncracked blood sample
US11137339B2 (en) Method for performing a blood count and determining the morphology of a blood smear
US8472693B2 (en) Method for determining at least one hemoglobin related parameter of a whole blood sample
US8361799B2 (en) Method and apparatus for determining the hematocrit of a blood sample utilizing the intrinsic pigmentation of hemoglobin contained within the red blood cells
US9291617B2 (en) Method and apparatus for analyzing individual cells or particulates using fluorescent quenching and/or bleaching
Golan et al. Noninvasive imaging of flowing blood cells using label-free spectrally encoded flow cytometry
CN1146354C (en) Method and apparatus for reflected imaging analysis
Casteleiro Costa et al. Noninvasive white blood cell quantification in umbilical cord blood collection bags with quantitative oblique back‐illumination microscopy
Schonbrun et al. Quantitative absorption cytometry for measuring red blood cell hemoglobin mass and volume
Kaza et al. Hemoglobin quantification in red blood cells via dry mass mapping based on UV absorption
Atkins et al. Using Raman spectroscopy to assess hemoglobin oxygenation in red blood cell concentrate: an objective proxy for morphological index to gauge the quality of stored blood?
Brandao et al. Impaired red cell deformability in iron deficient subjects
Halder et al. Digital camera-based spectrometry for the development of point-of-care anemia detection on ultra-low volume whole blood sample
Paul et al. Quantitative absorption imaging of red blood cells to determine physical and mechanical properties
M’boh et al. The effect of falciparum malaria infection on the quantity of trace elements (iron, copper, zinc) in the blood in children of Côte d’Ivoire
Arcot et al. Developing microscopy based microfluidic SLS assay for on-chip hemoglobin estimation
FR3034524A1 (en) METHOD FOR DETERMINING THE AGGLUTINATION LEVEL OF PARTICLES IN A SAMPLE
Soysal et al. Raman tweezers as an alternative diagnostic tool for paroxysmal nocturnal hemoglobinuria
WO2023242387A1 (en) Automated fluorescence-based quantification of pocked red cells
Grafit et al. Estimation of original volume of dry bloodstains using spectrophotometric method
Alqahtany EDTA-DEPENDENT PSEUDOTHROMBOCYTOPENIA: AN INSIGHT INTO THE ANALYSIS OF TRUE LOW AND FALSE LOW PLATELET COUNT AMONG SAUDI POPULATION
JP2000329762A (en) Method for preparing white blood cell measuring reagent and white blood cell measuring sample
Naumenko et al. Spectral transmission by the specimens of blood-glucose mixture

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170929

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181016

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 15/10 20060101ALI20181010BHEP

Ipc: G02B 21/36 20060101ALI20181010BHEP

Ipc: G01N 33/49 20060101AFI20181010BHEP

Ipc: G01N 15/14 20060101ALI20181010BHEP

Ipc: G01N 15/00 20060101ALI20181010BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20211104

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220315